Zymeworks Inc (ZYME)
9.58
-0.17 (-1.74%)
USD |
NYSE |
Jan 27, 16:00
9.50
-0.08 (-0.84%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 554.61M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 15.42% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 17.58 |
| Price to Book Value | 2.495 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 91.81% |
News
Headline
Wire
Time (ET)
MT Newswires
01/20 08:16
MT Newswires
01/19 12:27
PR Newswire
01/19 08:49
PR Newswire
01/19 07:45
SA Breaking News
01/13 15:00
MT Newswires
01/04 17:28
SA Breaking News
01/04 17:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/24/2023* | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/24/2023* | -- | Results | Q4 2022 | -- | 3.11 | -- | |
| 11/08/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/08/2022 | -- | Results | Q3 2022 | -- | -0.97 | -- | |
| 08/04/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.97 | -0.94 | -2.75% | |
| 05/04/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/04/2022 | -- | Results | Q1 2022 | -1.19 | -0.76 | -57.41% |
*Estimated Date/Time
Earnings
Profile
Edit
| Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
| URL | https://www.zymeworks.com |
| Investor Relations URL | https://ir.zymeworks.com/ |
| HQ State/Province | British Columbia |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 08, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
| Revenue (TTM) | 31.62M |
| Total Expenses (TTM) | 271.98M |
| Net Income (TTM) | -236.98M |
| Total Assets (Quarterly) | 368.97M |
| Total Liabilities (Quarterly) | 146.69M |
| Shareholders Equity (Quarterly) | 222.28M |
| Cash from Operations (TTM) | -211.53M |
| Cash from Investing (TTM) | 39.15M |
| Cash from Financing (TTM) | 113.56M |
Ratings
Profile
Edit
| Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
| URL | https://www.zymeworks.com |
| Investor Relations URL | https://ir.zymeworks.com/ |
| HQ State/Province | British Columbia |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 08, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ZYME Tweets |